Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م26.41|
|52 Week High||ج.م14.75|
|52 Week Low||ج.م44.90|
|1 Month Change||-12.87%|
|3 Month Change||-24.39%|
|1 Year Change||55.90%|
|3 Year Change||n/a|
|5 Year Change||136.65%|
|Change since IPO||183.37%|
Recent News & Updates
|BIOC||EG Pharmaceuticals||EG Market|
Return vs Industry: BIOC exceeded the EG Pharmaceuticals industry which returned 2.2% over the past year.
Return vs Market: BIOC exceeded the EG Market which returned 8.2% over the past year.
Stable Share Price: BIOC is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BIOC's weekly volatility (7%) has been stable over the past year.
About the Company
|1981||n/a||Amr Mamdouh Majid||https://www.gsk.com/en-gb/contact-us/worldwide/egypt|
GlaxoSmithKline S.A.E. operates as a research-based pharmaceutical and healthcare company. It offers a range of prescription medicines, vaccines, and consumer healthcare products. The company was founded in 1981 and is based in Cairo, Egypt.
GlaxoSmithKlineE Fundamentals Summary
|BIOC fundamental statistics|
Is BIOC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIOC income statement (TTM)|
|Cost of Revenue||ج.م1.04b|
Last Reported Earnings
Sep 30, 2020
Next Earnings Date
|Earnings per share (EPS)||2.12|
|Net Profit Margin||9.17%|
How did BIOC perform over the long term?See historical performance and comparison
1.9%Current Dividend Yield
Is GlaxoSmithKlineE undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BIOC (EGP26.41) is trading above our estimate of fair value (EGP6.94)
Significantly Below Fair Value: BIOC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIOC is poor value based on its PE Ratio (12.5x) compared to the EG Pharmaceuticals industry average (5.5x).
PE vs Market: BIOC is poor value based on its PE Ratio (12.5x) compared to the EG market (12.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIOC is overvalued based on its PB Ratio (1.7x) compared to the EG Pharmaceuticals industry average (1.3x).
How is GlaxoSmithKlineE forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKlineE has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has GlaxoSmithKlineE performed over the past 5 years?
Last years revenue growth
Earnings and Revenue History
Quality Earnings: BIOC has a high level of non-cash earnings.
Growing Profit Margin: BIOC became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BIOC has become profitable over the past 5 years.
Accelerating Growth: BIOC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BIOC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).
Return on Equity
High ROE: BIOC's Return on Equity (13.8%) is considered low.
How is GlaxoSmithKlineE's financial position?
Financial Position Analysis
Short Term Liabilities: BIOC's short term assets (EGP1.4B) exceed its short term liabilities (EGP875.1M).
Long Term Liabilities: BIOC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BIOC's debt to equity ratio (19.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BIOC's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BIOC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BIOC's interest payments on its debt are well covered by EBIT (3.9x coverage).
What is GlaxoSmithKlineE current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIOC's dividend (1.89%) isn’t notable compared to the bottom 25% of dividend payers in the EG market (2.69%).
High Dividend: BIOC's dividend (1.89%) is low compared to the top 25% of dividend payers in the EG market (7.43%).
Stability and Growth of Payments
Stable Dividend: BIOC is not paying a notable dividend for the EG market, therefore no need to check if payments are stable.
Growing Dividend: BIOC is not paying a notable dividend for the EG market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIOC's dividend in 3 years as they are not forecast to pay a notable one for the EG market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Amr Mamdouh Majid
Dr. Amr Mamdouh Abdel Majid serves as Chairman, Managing Director and Executive Director of GlaxoSmithKline S.A.E.
Experienced Management: BIOC's management team is considered experienced (2.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GlaxoSmithKline S.A.E's employee growth, exchange listings and data sources
- Name: GlaxoSmithKline S.A.E
- Ticker: BIOC
- Exchange: CASE
- Founded: 1981
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م2.206b
- Shares outstanding: 83.51m
- Website: https://www.gsk.com/en-gb/contact-us/worldwide/egypt
- GlaxoSmithKline S.A.E
- Boomerang Building
- No 46, Block J First Section City Centre
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 14:31|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.